Stock Watch: The Great Post-Pandemic Pharmaceutical Marketing Debate
Is Remote Pharmaceutical Marketing Replacing Traditional Field Forces?
Virtual marketing was the logical way to interact with healthcare professionals during the pandemic. It may stay after the pandemic but could be an additional expense.
You may also be interested in...
From clinical trials to in-person sales calls, the pharmaceutical value chain has been tested by the COVID-19 pandemic, but has held up. Nevertheless, recent friction within this chain may be more than a passing irritation.
Depending on the therapeutic area, a fall in pharmaceutical sales was an obvious effect of the pandemic, although lower selling and marketing expenses and fewer non-COVID-19 infections were minor positives.
Another blow-out quarter from Pfizer provided the impetus for an acquisition. But the history of recent commercial-stage biotech transactions and the risky nature of all early-stage companies suggest that the floodgates will not burst open.